Von Willebrand Disease in Children
Von Willebrand disease (vWD) is a complex bleeding disorder with a defective hemostasis function. Erik von Willebrand first reported the disease in 1926 and believed it was caused by abnormal platelet function or vascular abnormalities. Pediatric patients are often caused by family inheritance. It is a common hereditary bleeding disease that can affect both men and women. It is now clear that abnormalities in the quality or quantity of von Willebrand Factor (vWF) cause vWD, accompanied by a decrease in the procoagulant activity of factor VII (VIII:C). Clinically, there are varying degrees of skin and mucosal bleeding tendencies, reduced platelet adhesion, and prolonged bleeding time. Acquired von Willebrand disease can occur on the basis of a variety of diseases, and a small number of patients may have no underlying diseases. It is rare in children.
-
Site of disease:
Blood vessels -
Infectious :
Not contagious -
Frequent population:
child -
Related symptoms:
Skin and mucous membrane bleeding intracranial hemorrhage repeated bleeding trauma gingival bleeding -
Concurrent disease:
Related Drugs
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization; 2. It is used for traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands; 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase; 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological local increased fibrinolysis in the uterine cavity; 5. It is used for mild bleeding caused by central nervous system diseases, such as subarachnoid hemorrhage and intracranial aneurysm bleeding. The use of this product for hemostasis is superior to other anti-fibrotic drugs.
Related Ingredients